Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524001 | 0.93 | POLB (0.41) | POLBF10OPRM1OPRL1ALDH1A1 | |
| SCHEMBL2814706 | 0.93 | POLB (0.44) | POLBF10OPRM1OPRL1ALDH1A1 | |
| SCHEMBL4087871 | 0.84 | AKT1 (0.43) | POLBPDE2A | |
| SCHEMBL14672673 | 0.83 | GAA (0.41) | POLBF10OPRM1OPRL1ALDH1A1 | |
| SCHEMBL27853653 | 0.82 | OPRM1 (0.49) | POLBOPRM1OPRL1ALDH1A1L3MBTL1 | |
| SCHEMBL21162019 | 0.82 | POLB (0.47) | POLBF10ALDH1A1L3MBTL1GAA | |
| SCHEMBL20476086 | 0.80 | ALDH1A1 (0.39) | POLBALDH1A1L3MBTL1PDE2AMAPT | |
| SCHEMBL23778505 | 0.79 | HIF1A (0.39) | POLBF10OPRM1OPRL1ALDH1A1 | |
| SCHEMBL12134686 | 0.79 | AKT1 (0.41) | POLBALDH1A1L3MBTL1PDE2A | |
| SCHEMBL21162018 | 0.78 | MAPT (0.44) | POLBALDH1A1L3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-110300754-A | Pyrrolo [1,2-b ] pyridazine derivatives | 吉利德科学公司 | 2019-10-01 | — | — | CN | disclosed |
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | POLB 171/4885F10 4000/4885OPRM1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.